Market Overview

UPDATE: Deutsche Bank Ups PT to $45 on Medtronic on Top-Line Beat

Related MDT
UPDATE: Credit Suisse Reiterates On Medtronic As Solid F2Q Showcases New Product Strength
#PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York
JPM Denies Report of Second Hack Attack (Fox Business)

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) and raised its price target from $43 to $45.

Deutsche Bank noted, "In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42,65 on Tuesday.

Latest Ratings for MDT

DateFirmActionFromTo
Nov 2014WedbushMaintainsNeutral
Nov 2014JefferiesMaintainsBuy
Nov 2014JP MorganMaintainsOverweight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters